Recently using genome-wide methylation data analysis, five-methylation signature (SLC39A14, PREX2, KCNIP2, CORO6, and EFNB1) were reported as novel independent prognostic biomarker for patients with ovarian serous cystadenocarcinoma, which significantly associated with OS of patients. Here, PREX2 is linked to ovarian serous cystadenocarcinoma.